DK0877760T3 - MHC-kpmplekser og anvendelse deraf - Google Patents

MHC-kpmplekser og anvendelse deraf

Info

Publication number
DK0877760T3
DK0877760T3 DK97905709T DK97905709T DK0877760T3 DK 0877760 T3 DK0877760 T3 DK 0877760T3 DK 97905709 T DK97905709 T DK 97905709T DK 97905709 T DK97905709 T DK 97905709T DK 0877760 T3 DK0877760 T3 DK 0877760T3
Authority
DK
Denmark
Prior art keywords
mhc
complexes
peptide
image
covalently linked
Prior art date
Application number
DK97905709T
Other languages
Danish (da)
English (en)
Inventor
Peter R Rhode
Hing C Wong
Jin-An Jiao
Martin Burkhardt
Original Assignee
Altor Bioscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altor Bioscience Corp filed Critical Altor Bioscience Corp
Application granted granted Critical
Publication of DK0877760T3 publication Critical patent/DK0877760T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
DK97905709T 1996-01-31 1997-01-30 MHC-kpmplekser og anvendelse deraf DK0877760T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/596,387 US5869270A (en) 1996-01-31 1996-01-31 Single chain MHC complexes and uses thereof
EP97905709A EP0877760B1 (en) 1996-01-31 1997-01-30 Mhc complexes and uses thereof

Publications (1)

Publication Number Publication Date
DK0877760T3 true DK0877760T3 (da) 2004-12-20

Family

ID=24387103

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97905709T DK0877760T3 (da) 1996-01-31 1997-01-30 MHC-kpmplekser og anvendelse deraf

Country Status (9)

Country Link
US (3) US5869270A (cg-RX-API-DMAC7.html)
EP (2) EP1526141A3 (cg-RX-API-DMAC7.html)
JP (1) JP2000515363A (cg-RX-API-DMAC7.html)
AT (1) ATE276275T1 (cg-RX-API-DMAC7.html)
AU (1) AU729672B2 (cg-RX-API-DMAC7.html)
CA (1) CA2244755A1 (cg-RX-API-DMAC7.html)
DE (1) DE69730693T2 (cg-RX-API-DMAC7.html)
DK (1) DK0877760T3 (cg-RX-API-DMAC7.html)
WO (1) WO1997028191A1 (cg-RX-API-DMAC7.html)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869270A (en) * 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
AU729406B2 (en) 1996-03-28 2001-02-01 Johns Hopkins University, The Soluble divalent and multivalent heterodimeric analogs of proteins
US6211342B1 (en) * 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
DE69840600D1 (de) * 1997-09-16 2009-04-09 Univ Oregon Health & Science Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t-zellen
US20030007978A1 (en) * 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US6232445B1 (en) * 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
GB2339782A (en) * 1998-06-05 2000-02-09 Philip Michael Savage Chimeric protein complexes comprising HLA class I antigens
IL144845A0 (en) * 1999-03-03 2002-06-30 Univ Pennsylvania Vaccines and gene therapy compositions and methods of making and using the same
ATE322683T1 (de) * 1999-04-16 2006-04-15 Ortho Mcneil Pharm Inc Verfahren zur detektion von antigenspezifischen t-zellen
AU4700100A (en) * 1999-05-06 2000-11-21 Wake Forest University Compositions and methods for identifying antigens which elicit an immune response
FR2796953B1 (fr) * 1999-07-29 2003-10-10 Centre Nat Rech Scient Proteines recombinantes, et complexes moleculaires derives de ces proteines, analogues a des molecules impliquees dans les reponses immunitaires
US6995237B1 (en) * 1999-10-27 2006-02-07 Cel-Sci Corporation Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions
US6316256B1 (en) * 2000-01-03 2001-11-13 Tr Associates, L.L.C. Method for protein transfer
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CA2404489A1 (en) * 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
US20020006397A1 (en) * 2000-04-28 2002-01-17 Roberts Bruce L. In VIVO loading of MHC
CA2410642A1 (en) * 2000-05-25 2001-11-29 Sunol Molecular Corporation Modulation of t-cell receptor interactions
GB0110547D0 (en) * 2001-04-30 2001-06-20 Avidex Ltd Method
US6811785B2 (en) * 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras
CA2487779C (en) 2001-06-05 2012-10-02 Altor Bioscience Corporation P53 binding t cell receptor molecules and uses thereof
US8022190B2 (en) * 2001-06-19 2011-09-20 Technion Research & Development Foundation Ltd. Immuno-molecules containing viral proteins, compositions thereof and methods of using
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
WO2003029475A1 (fr) * 2001-09-28 2003-04-10 Dnavec Research Inc. Vecteur viral infectant une cellule de mammifere, codant pour la $g(b)2m liee a un epitope
CN1617888A (zh) * 2002-01-18 2005-05-18 伊诺维奥埃斯 用于肌内给药的双特异性抗体dna的构建
US20030199024A1 (en) * 2002-04-19 2003-10-23 Hansen Ted H. Single chain trimers of class I MHC molecules
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
AU2003253684A1 (en) * 2002-06-28 2004-01-19 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
DE60334474D1 (de) * 2002-07-12 2010-11-18 Univ Johns Hopkins Reagenzien und verfahren zum eingriff in einzigartige klonotype lymphozyten-rezeptoren
US8314210B2 (en) * 2002-07-12 2012-11-20 Dana-Farber Cancer Institute, Inc. Compositions and methods for the generation of MHC class II compounds by peptide exchange
CA2500413A1 (en) * 2002-10-01 2004-04-15 Dnavec Research Inc. Method of strengthening foreign epitope presentation by mhc class i by inhibiting tap activity
CA2501946C (en) * 2002-10-16 2014-12-23 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
EP2316844A3 (en) * 2003-05-21 2011-07-20 Biotech Tools S.A. Peptide complex
DK1625148T3 (da) 2003-05-21 2013-01-14 Biotech Tools Sa Peptidkompleks
EP2783699A1 (en) 2003-09-05 2014-10-01 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
CN1901839A (zh) 2003-11-10 2007-01-24 阿尔特生物科学公司 可溶性tcr分子及其用途
US20050227351A1 (en) * 2004-04-08 2005-10-13 Awdalla Essam T Methods and compound protein molecules used for inducing cytotoxic cell-mediated immune response in a mammal against a pathogenic cell
DE102004019803A1 (de) * 2004-04-23 2005-11-10 Imusyn Gmbh & Co.Kg Verfahren zur Herstellung löslicher MHC-Proteine
GB2422834B8 (en) * 2005-02-04 2007-01-04 Proimmune Ltd MHC oligomer and method of making the same
EP1982176A1 (en) * 2006-01-30 2008-10-22 Dako Denmark A/S High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
US8518697B2 (en) * 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
US7977457B2 (en) * 2006-05-19 2011-07-12 Teva Pharmaceutical Industries Ltd. Fusion proteins, uses thereof and processes for producing same
EP2155782A2 (en) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2167536A1 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
US10722562B2 (en) * 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US20110124019A1 (en) * 2009-11-25 2011-05-26 The Charlotte-Mecklenburg Hospital Authority Method of using carbonic anhydrase to detect hemolysis
JP5665021B2 (ja) * 2010-03-08 2015-02-04 国立大学法人東京農工大学 融合ｍｈｃ分子連結磁気微粒子、抗原ペプチドのスクリーニング方法、組換えベクター、及び磁性細菌の形質転換体
WO2011147894A1 (en) 2010-05-25 2011-12-01 Forschungsverbund Berlin E.V. Chimeric mhc class ii proteinpeptide
GB201013767D0 (en) * 2010-08-17 2010-09-29 Isis Innovation Identification of ligands and their use
WO2012145384A1 (en) 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
US8753309B2 (en) 2011-06-24 2014-06-17 The Invention Science Fund I, Llc Device, system, and method including micro-patterned cell treatment array
US10228312B2 (en) 2012-02-23 2019-03-12 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
US10274499B2 (en) 2012-03-27 2019-04-30 The University Of Western Ontario SH2 domain variants
PT2838548T (pt) * 2012-04-17 2023-10-13 Univ Washington Through Its Center For Commercialization Células deficientes em hla de classe ii, células deficientes em hla de classe i capazes de expressar proteínas de hla de classe ii, e utilizações das mesmas
JP6445427B2 (ja) * 2012-05-08 2018-12-26 ウエスタン ユニバーシティ オブ ヘルス サイエンシズ ＣＤ４＋Ｔ細胞集団の抗原特異的な拡大のために標準化されたｅｘｖｉｖｏプラットフォーム
EP3640375A3 (en) 2012-12-11 2020-07-29 Albert Einstein College of Medicine Methods for high throughput receptor/ligand identification
WO2014141244A1 (en) 2013-03-12 2014-09-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Synthetic peptides for the treatment of autoimmune diseases
GB201313352D0 (en) 2013-07-26 2013-09-11 Isis Innovation Identification of peptide ligands
PT3480213T (pt) * 2014-06-18 2020-02-04 Albert Einstein College Medicine Polipéptidos syntac e utilizações dos mesmos
US20160081314A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors
WO2017068419A2 (en) 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
WO2017201131A1 (en) 2016-05-18 2017-11-23 Albert Einstein College Of Medicine, Inc. Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof
BR112018073606A2 (pt) 2016-05-18 2019-02-26 Cue Biopharma, Inc. polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos
CN109963584B (zh) 2016-09-06 2024-03-15 豪夫迈·罗氏有限公司 结合mhc的肽阵列及其使用方法
WO2018119114A1 (en) 2016-12-22 2018-06-28 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3596118B1 (en) 2017-03-15 2024-08-21 Cue Biopharma, Inc. Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
WO2018197949A1 (en) 2017-04-27 2018-11-01 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers
AU2020204994A1 (en) * 2019-01-03 2021-07-29 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
AU2021272895A1 (en) 2020-05-12 2022-09-22 Cue Biopharma, Inc. Multimeric T-cell modulatory polypeptides and methods of use thereof
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
US11926667B2 (en) 2020-10-13 2024-03-12 Janssen Biotech, Inc. Bioengineered T cell mediated immunity, materials and other methods for modulating cluster of differentiation IV and/or VIII

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0420913B1 (en) * 1988-06-14 1995-11-15 Cell Med, Inc. Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same
US5130297A (en) * 1988-06-23 1992-07-14 Anergen, Inc. Conjugates useful in ameliorating autoimmunity MHC-II-peptide
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
US5976551A (en) * 1991-11-15 1999-11-02 Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale Altered major histocompatibility complex (MHC) determinant and method of using the determinant
WO1993009810A1 (en) * 1991-11-19 1993-05-27 Anergen, Inc. Mhc subunit conjugates useful in ameliorating deleterious immune responses
WO1993010220A1 (en) * 1991-11-19 1993-05-27 Anergen, Inc. Soluble mhc molecules and their uses
US5583031A (en) * 1992-02-06 1996-12-10 President And Fellows Of Harvard College Empty major histocompatibility class II heterodimers
US5314813A (en) * 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
AU6270794A (en) * 1993-02-25 1994-09-14 Anergen, Inc. Treatment of allergic responses using mhc-peptide complexes
WO1994025054A1 (en) * 1993-04-29 1994-11-10 Andrew Atkin Recombinant vaccine
US5820866A (en) * 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
AU696177B2 (en) * 1994-07-29 1998-09-03 Sunol Molecular Corporation Mhc complexes and uses thereof
US5888773A (en) 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
EP0833930A2 (en) * 1995-06-07 1998-04-08 ZymoGenetics, Inc. Fused soluble mhc heterodimer:peptide complexes and their uses
US5869270A (en) * 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
AU729406B2 (en) * 1996-03-28 2001-02-01 Johns Hopkins University, The Soluble divalent and multivalent heterodimeric analogs of proteins
US6232445B1 (en) * 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof

Also Published As

Publication number Publication date
DE69730693D1 (de) 2004-10-21
JP2000515363A (ja) 2000-11-21
EP1526141A2 (en) 2005-04-27
AU729672B2 (en) 2001-02-08
AU2253897A (en) 1997-08-22
US6309645B1 (en) 2001-10-30
EP1526141A3 (en) 2005-08-24
EP0877760A4 (cg-RX-API-DMAC7.html) 1998-12-30
CA2244755A1 (en) 1997-08-07
DE69730693T2 (de) 2005-10-06
EP0877760A1 (en) 1998-11-18
WO1997028191A1 (en) 1997-08-07
EP0877760B1 (en) 2004-09-15
US7141656B2 (en) 2006-11-28
US5869270A (en) 1999-02-09
US20020034513A1 (en) 2002-03-21
ATE276275T1 (de) 2004-10-15

Similar Documents

Publication Publication Date Title
DK0877760T3 (da) MHC-kpmplekser og anvendelse deraf
CA2196085A1 (en) Mhc complexes and uses thereof
ATE370967T1 (de) Polyspezifische bindemoleküle und deren verwendung
ATE533784T1 (de) Lösliche, einzelkettige proteine des t- zellrezeptors
GR3020611T3 (en) Cell-free receptor binding tests, their production and use
HU9201687D0 (en) Preparation of sets from peptid mixtures with polycomponents and their use for the identification of biologically active peptides
DK1012274T3 (da) Dödsdomæneholdig receptor-4 (DR4: dödsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L)
CY1110689T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια
PT1032660E (pt) Processo de identificação dos domínios do sítio de ligação que retêm a capacidade de ligação a um epítope
DK0934526T3 (da) Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål
ES2171581T3 (es) Procedimiento a base de fagemidos de produccion de fragmentos de bacteriofagos filamentosos que presentan moleculas de anticuerpos y los fragmentos de bacteriofagos correspondientes.
NO963018L (no) CTLA4-mutantmolekyler og anvendelser derav
DE69710360D1 (de) Testverfahren für peptidspezifische t-zellen
PT762901E (pt) Peptidos marcados com tecnecio-99m para imagiologia.
DE59914490D1 (de) Ein faktor viii-polypeptid mit faktor viii:c-aktivität
NO962084L (no) DNA sekvens som koder for en BMP reseptor
DE69333382D1 (de) Hyaluronan rezeptor (rezeptor durch hyaluronan verurzachte bewelichkeit) und hyaluronan bindende peptide
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
ATE405582T1 (de) P53 bindende t-zellrezeptormoleküle und deren verwendungen
ES2150495T3 (es) Ligandos de flt3 purificados de mamifero y agonistas y antagonistas de los mismos.
CA2301709A1 (en) Epitope-bearing major histocompatibility complex class ii element/immunoglobulin chimeric molecules
Harmand Molecular interface characterization in human bone matrix: I. Biochemical and IR spectroscopic studies
WO1996021028A3 (en) Soluble heterodimeric t cell receptors and their antibodies
Löster et al. Analysis of protein aggregates by combination of cross-linking reactions and chromatographic separations
EA200400384A1 (ru) Растворимый рецептор т-клетки